Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DiNardo

Showing results (871-880 of 1,482) with videos related to

Pageof 149
Sort By:
Annals of Hematology|March 8, 2023
Estimated glomerular filtration rate in Brazilian adults with sickle cell disease: results from the REDS-III multicenter cohort studyAndré Rolim Belisário, Ana Cristina Simões E Silva, Isabel Cristina Gomes Moura, et al.
The Lancet. Haematology|January 17, 2017
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trialPreetesh Jain, Michael Keating, Sarah Renner, et al.
Blood Cancer Journal|April 13, 2023
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
The Lancet. Oncology|January 18, 2018
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyCourtney D DiNardo, Keith W Pratz, Anthony Letai, et al.
Blood Advances|January 4, 2018
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosisPrajwal Boddu, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
PLOS Global Public Health|July 24, 2025
Mortality from sickle cell disease in BrazilPaula Fraiman Blatyta Caselli, Claudia Di Lorenzo Oliveira, Isabel Gomes, et al.
The Lancet. Haematology|October 11, 2025
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trialGuillaume Richard-Carpentier, Gopila Gupta, Charina Koraksic, et al.
The Lancet. Haematology|July 30, 2021
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trialTapan M Kadia, Patrick K Reville, Gautam Borthakur, et al.
Genome Medicine|May 18, 2022
Rapid molecular diagnostics of tuberculosis resistance by targeted stool sequencingDoctor B Sibandze, Alexander Kay, Viola Dreyer, et al.
Cancer|March 9, 2023
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulationDaniel Nguyen, Hagop M Kantarjian, Nicholas J Short, et al.
Pageof 149

Showing results (871-880 of 1,482) with videos related to

Sort By:
Pageof 149
Annals of Hematology|March 8, 2023
Estimated glomerular filtration rate in Brazilian adults with sickle cell disease: results from the REDS-III multicenter cohort studyAndré Rolim Belisário, Ana Cristina Simões E Silva, Isabel Cristina Gomes Moura, et al.
The Lancet. Haematology|January 17, 2017
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trialPreetesh Jain, Michael Keating, Sarah Renner, et al.
Blood Cancer Journal|April 13, 2023
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
The Lancet. Oncology|January 18, 2018
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyCourtney D DiNardo, Keith W Pratz, Anthony Letai, et al.
Blood Advances|January 4, 2018
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosisPrajwal Boddu, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
PLOS Global Public Health|July 24, 2025
Mortality from sickle cell disease in BrazilPaula Fraiman Blatyta Caselli, Claudia Di Lorenzo Oliveira, Isabel Gomes, et al.
The Lancet. Haematology|October 11, 2025
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trialGuillaume Richard-Carpentier, Gopila Gupta, Charina Koraksic, et al.
The Lancet. Haematology|July 30, 2021
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trialTapan M Kadia, Patrick K Reville, Gautam Borthakur, et al.
Genome Medicine|May 18, 2022
Rapid molecular diagnostics of tuberculosis resistance by targeted stool sequencingDoctor B Sibandze, Alexander Kay, Viola Dreyer, et al.
Cancer|March 9, 2023
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulationDaniel Nguyen, Hagop M Kantarjian, Nicholas J Short, et al.
Pageof 149